ConductScience.org, home

Comparison · NCT02056431-600e9dca

IVR Control Group vs IVR Intervention Group: Number of Participants With Minimally Effective Dose in 12 Months

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. IVR Control Group vs IVR Intervention Group: Number of Participants With Minimally Effective Dose in 12 Months. Trial comparisons, record NCT02056431-600e9dca. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02056431-600e9dca

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4840.4450.523wilson
Risk in group 20.5170.4760.558wilson
Risk difference, group 1 minus group 2-0.0331-0.08990.024newcombe hybrid score
Risk ratio, group 1 over group 20.9360.8351.05log
Odds ratio, group 1 over group 20.8760.6971.1log
Number needed to treat, for one fewer participant with the outcome on IVR Control Group than on IVR Intervention Group30.2from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IVR Control GroupParticipants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th,and 6th months post start date) containing generic messages regarding diabetes education299618OG000
Group 2IVR Intervention Group
Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th,and 6th months post start date) to collect information on medication use, side effects, rating of side effects and pain symptoms to be fed back to their physicians
290561OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Minimally Effective Dose in 12 Months
Description
Count of patients who ever received a minimally effective dose of the medications they started on during the 12 months following treatment start (measured post only).
Time frame
12 months
Population
1179 Patient completed the close out survey

Source ClinicalTrials.gov

Trial

Title
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
NCT number
NCT02056431
Phases
NA
Conditions
Diabetic Peripheral Neuropathy
Interventions
IVR Intervention Group
Lead sponsor
Kaiser Permanente
Results first posted
2018-02-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02056431-600e9dca